175 related articles for article (PubMed ID: 30094806)
1. The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals.
Pennington B; Hernandez-Alava M; Pudney S; Wailoo A
Pharmacoeconomics; 2019 Jan; 37(1):75-84. PubMed ID: 30094806
[TBL] [Abstract][Full Text] [Related]
2. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
3. EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom.
Hernandez Alava M; Wailoo A; Grimm S; Pudney S; Gomes M; Sadique Z; Meads D; O'Dwyer J; Barton G; Irvine L
Value Health; 2018 Jan; 21(1):49-56. PubMed ID: 29304940
[TBL] [Abstract][Full Text] [Related]
4. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
5. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
6. To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study.
Ben ÂJ; van Dongen JM; Finch AP; Alili ME; Bosmans JE
Eur J Health Econ; 2023 Nov; 24(8):1253-1270. PubMed ID: 36371791
[TBL] [Abstract][Full Text] [Related]
7. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
8. An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis.
Wailoo A; Alava MH; Pudney S; Barton G; O'Dwyer J; Gomes M; Irvine L; Meads D; Sadique Z
Value Health; 2021 Apr; 24(4):568-574. PubMed ID: 33840435
[TBL] [Abstract][Full Text] [Related]
9. Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe.
Golicki D; Niewada M; Hout BV; Janssen MF; Pickard AS
Value Health Reg Issues; 2014 Sep; 4():19-23. PubMed ID: 29702801
[TBL] [Abstract][Full Text] [Related]
10. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
Tosh JC; Longworth LJ; George E
Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
[TBL] [Abstract][Full Text] [Related]
11. Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals.
Pennington BM
Value Health; 2020 Oct; 23(10):1349-1357. PubMed ID: 33032779
[TBL] [Abstract][Full Text] [Related]
12. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
13. A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents.
Hill H; Rowen D; Pennington B; Wong R; Wailoo A
Value Health; 2020 Jul; 23(7):907-917. PubMed ID: 32762993
[TBL] [Abstract][Full Text] [Related]
14. Econometric modelling of multiple self-reports of health states: The switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis.
Hernández-Alava M; Pudney S
J Health Econ; 2017 Sep; 55():139-152. PubMed ID: 28778350
[TBL] [Abstract][Full Text] [Related]
15. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
16. Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
Kim H; Cook G; Goodall S; Liew D
Pharmacoecon Open; 2021 Sep; 5(3):459-467. PubMed ID: 33891268
[TBL] [Abstract][Full Text] [Related]
17. Mapping the COPD Assessment Test onto EQ-5D.
Hoyle CK; Tabberer M; Brooks J
Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
[TBL] [Abstract][Full Text] [Related]
18. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
Wong CKH; Lang BHH; Yu HMS; Lam CLK
Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
[TBL] [Abstract][Full Text] [Related]
19. Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL).
Williams K; Gibson A; McNamara L; Jones T; Lloyd AJ
J Med Econ; 2020 Oct; 23(10):1142-1150. PubMed ID: 32644862
[TBL] [Abstract][Full Text] [Related]
20. Head-to-Head Comparison of EQ-5D-3L and EQ-5D-5L Health Values.
Selivanova A; Buskens E; Krabbe PFM
Pharmacoeconomics; 2018 Jun; 36(6):715-725. PubMed ID: 29623559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
